Matthew L. Meyerson, MD, PhD, on Finding Links Between EGFR and KRAS Mutations in Lung Cancer Within Specific Populations

Posted: Wednesday, June 8, 2022

Matthew L. Meyerson, MD, PhD, of Dana-Farber Cancer Institute, discusses his research on the correlation of EGFR and KRAS mutations in lung cancer with specific Latin American ancestry groups. The findings may one day be applied clinically to detect cancers and/or their actionable driver mutations early, possibly helping to refine the molecular studies ordered for certain patients.